Knight Therapeutics (GUD) Stock Price, News & Analysis

Company Overview

Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.

Key Stats

• Today's Range: C$6.05 to C$6.25
• 50-Day Range: C$5.75 to C$6.21
• 52-Week Range: C$5.09 to C$6.45
• Volume: 164,416 shs
• Average Volume: 66,777 shs
• Market Capitalization: C$611.96 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: C$7.15
• Consensus Rating: Strong Buy

Knight Therapeutics Stock Analysis - MarketRank™

Knight Therapeutics scored higher than 21% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.8 / 5
• Analyst Rating: Strong Buy

Consensus Rating

Knight Therapeutics has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Knight Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Knight Therapeutics is -20.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Knight Therapeutics is -20.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

Due to a projected decrease in earnings for Knight Therapeutics, their PEG ratio cannot be calculated.

Price to Book Value per Share Ratio

Knight Therapeutics has a P/B Ratio of 0.79. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for GUD.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Knight Therapeutics does not currently pay a dividend.

Dividend Growth

Knight Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for GUD.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Knight Therapeutics this week, compared to 1 article on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Knight Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

45.62% of the stock of Knight Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 12.58% of the stock of Knight Therapeutics is held by institutions.

GUD Stock Analysis - Frequently Asked Questions

How have GUD shares performed this year?

Knight Therapeutics' stock was trading at C$5.34 at the start of the year. Since then, GUD shares have increased by 13.3% and is now trading at C$6.05.

How do I buy shares of Knight Therapeutics?

Shares of GUD stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of Knight Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Knight Therapeutics investors own include ARC Resources (ARX), Cenovus Energy (CVE), Enbridge (ENB), Whitecap Resources (WCP), Bombardier, Inc. Class B (BBD.B), Crescent Point Energy (CPG) and Suncor Energy (SU).

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: TSE:GUD
• CIK: N/A
• Web: www.gud-knight.com
• Phone: 514-484-4483
• Fax: N/A
• Employees: 725
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Knight Therapeutics: C$7.15
• High Price Target: C$7.50
• Low Price Target: C$6.50
• Potential Upside/Downside: +18.2%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): C($0.30)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 59.93
• P/E Growth: -1013.5
• Net Income: -C$30.73 million
• Net Margins: -8.81%
• Pretax Margin: N/A
• Return on Equity: -4.04%
• Return on Assets: 0.51%

Debt

• Debt-to-Equity Ratio: 7.52
• Current Ratio: 3.36
• Quick Ratio: 1.79

Sales & Book Value

• Annual Sales: C$348.70 million
• Price / Sales: 1.75
• Cash Flow: C$1.57 per share
• Price / Cash Flow: 3.85
• Book Value: C$7.65 per share
• Price / Book: 0.79

Miscellaneous

• Outstanding Shares: 101,150,053
• Free Float: N/A
• Market Cap: C$611.96 million
• Optionable: Not Optionable
• Beta: 0.50